Covis is led by one of the strongest and longest-tenured senior management teams committed to delivering therapeutic solutions to improve the lives of its patients.
Through its operational excellence, Covis is the preferred partner to world-class pharmaceutical companies and contract manufacturing organizations.
Covis offers a portfolio of pharmaceutical products providing patients with affordable and therapeutically equivalent medications of select brands.
At Covis, our paramount concern is patients' outcomes as we focus on improving the health of people with serious medical conditions.
Covis is always evaluating products and corporate acquisition opportunities. Covis is well-capitalized and has significant resources committed from its equity sponsors for tack-on deals and larger transaction opportunities.
Covis has unparalleled expertise across all functional areas with a flawless history of executing commercial onboarding, tech transferring, and launching authorized generic and line extension products.
Covis is always evaluating products and corporate acquisition opportunities with significant resources committed from its equity sponsors for tack-on deals and larger transaction opportunities. For all partnering inquiries, please contact us.
Covis is devoted to developing new therapeutic solutions to improve patients' quality of life through line extensions of its existing portfolio as well as selected novel late-stage clinical programs.
Product information is intended for residents of the United States only. Lanoxin® is a registered trademark of the GlaxoSmithKline group of companies. Rilutek® is a registered trademark of the Sanofi-Aventis group of companies. Betapace® and BetapaceAF® are registered trademarks of BAYER Schering Pharma AG. Altoprev® is a registered trademark of Shionogi Inc. Sular® is a registered trademark of Shionogi Inc. Alvesco®, Omnaris®, and Zetonna® are registered trademarks of Takeda GmbH.
July 13, 2017
March 9, 2015
April 4, 2013